Ambit Biosciences FDA issues are fixable, says RW Baird Baird remains a buyer of Ambit Biosciences as they believe the issues with the FDA are fixable. The firm expects the issues to be resolved without additional clinical work and continues to expect a 2016 launch for its AML treatment. Shares are Buy rated with a $17 price target.
News For AMBI From The Last 14 Days
Check below for free stories on AMBI the last two weeks.